A Case of Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Metaplastic Breast Cancer

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00506 JCO Precision Oncology no. 7 (2023) e2200506. Published online May 17, 2023. PMID: 37196220 A Case of Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Metaplastic Breast Cancer Anita Gul , MD1xAnita GulSearch for articles by this author; J. Jaime Alberty-Oller , MD, FACS2xJ. Jaime Alberty-OllerSearch for articles by this author; Jagbir Sandhu, MD1xJagbir SandhuSearch for articles by this author; Everick Ayala-Bustamante, MD2xEverick Ayala-BustamanteSearch for articles by this author; and Sylvia Adams , MD3xSylvia AdamsSearch for articles by this author Show More 1New York Medical College, Metropolitan Hospital, New York, NY2SUNY Downstate Health Sciences Center, Kings County Hospital, Brooklyn, NY3Perlmutter Cancer Center, NYU Langone Health, New York, NY https://doi.org/10.1200/PO.22.00506 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyDATA SHARING STATEMENTAll the data supporting the findings in this case report are contained within the text.AUTHOR CONTRIBUTIONSConception and design: Anita Gul, Jagbir Sandhu, Sylvia AdamsCollection and assembly of data: Anita Gul, J. Jaime Alberty-Oller, Jagbir Sandhu, Everick Ayala-BustamanteData analysis and interpretation: Anita Gul, Jagbir Sandhu, Everick Ayala-Bustamante, Sylvia AdamsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).J. Jaime Alberty-OllerHonoraria: HologicConsulting or Advisory Role: HologicTravel, Accommodations, Expenses: HologicSylvia AdamsConsulting or Advisory Role: Merck, Genentech, Bristol Myers SquibbResearch Funding: Merck (Inst), Genentech (Inst), Celgene (Inst), Bristol Myers Squibb (Inst), Amgen (Inst), Novartis (Inst)No other potential conflicts of interest were reported.